Murphy, G P <br/><br/>
Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease.  [electronic resource] 

 -  The Prostate  Jan 1999 
 - 73-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0270-4137 
<br/><br/><label>Standard No.: </label>10.1002/(sici)1097-0045(19990101)38:1<73::aid-pros9>3.0.co;2-v  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antigens, Neoplasm--administration & dosage<br/>Antigens, Surface<br/>Bone Neoplasms--diagnostic imaging<br/>Cancer Vaccines--administration & dosage<br/>Carboxypeptidases--administration & dosage<br/>Dendritic Cells<br/>Glutamate Carboxypeptidase II<br/>HLA-A2 Antigen--administration & dosage<br/>Hormones--therapeutic use<br/>Humans<br/>Infusions, Intravenous<br/>Male<br/>Middle Aged<br/>Prostatic Neoplasms--drug therapy<br/>Radionuclide Imaging<br/>Treatment Outcome<br/>Vaccines, Synthetic--administration & dosage